0001562180-22-001475.txt : 20220215
0001562180-22-001475.hdr.sgml : 20220215
20220215164200
ACCESSION NUMBER: 0001562180-22-001475
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20220211
FILED AS OF DATE: 20220215
DATE AS OF CHANGE: 20220215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: IGUCHI KIMI
CENTRAL INDEX KEY: 0001304815
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36544
FILM NUMBER: 22639765
MAIL ADDRESS:
STREET 1: 100 FOXBOROUGH BOULEVARD
STREET 2: SUITE 240
CITY: FOXBOROUGH
STATE: MA
ZIP: 02035
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sage Therapeutics, Inc.
CENTRAL INDEX KEY: 0001597553
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-299-8380
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2022-02-11
false
0001597553
Sage Therapeutics, Inc.
SAGE
0001304815
IGUCHI KIMI
C/O SAGE THERAPEUTICS, INC.
215 FIRST STREET
CAMBRIDGE
MA
02142
false
true
false
false
CFO & Treasurer
Stock Option (Right to Buy)
43.04
2022-02-11
4
A
false
15200.00
0.00
A
2032-02-11
Common Stock
15200.00
15200.00
D
The securities awarded on February 11, 2022 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 3,800 shares of common stock shall vest on the one year anniversary of February 11, 2022, with 11,400 shares vesting in 36 equal monthly installments thereafter.
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Kimi Iguchi
2022-02-15
EX-24
2
kimiiguchipoa2019.txt
KIMI IGUCHI POA 2019
POWER OF ATTORNEY
I, the undersigned, hereby authorize and designate Anne Marie
Cook (SVP, General Counsel), Erin Lanciani (SVP, People and
Organizational Strategy), and Jennifer Fitzpatrick (Vice President,
Corporate Counsel) for as long as they remain employees of Sage
Therapeutics, Inc., and Laurie Burlingame of Goodwin Procter, each
acting singly, or their successors in role, to take the following
actions, acting as my agent and attorney-in-fact, with full power of
substitution:
(1) to prepare and sign on my behalf any Form 3, Form 4 or
Form 5 pursuant to Section 16 of the Securities Exchange Act of 1934,
as amended, and to file the same with the Securities and Exchange
Commission, NASDAQ, NYSE, and each stock exchange on which shares of
Common Stock or other securities of Sage Therapeutics, Inc. are
listed, as required by law;
(2) to prepare and sign on my behalf any Form 144
pursuant to the Securities Act of 1933, as amended, and to file the
same with the Securities and Exchange Commission, NASDAQ, NYSE, and
each stock exchange on which shares of Common Stock or other
securities of Sage Therapeutics, Inc. are listed, as required by law;
and
(3) take any other action necessary or proper in
connection with the foregoing.
Unless earlier revoked under the next sentence, this Power of
Attorney shall remain in effect as long as I am an executive officer
or director of Sage Therapeutics, Inc., and shall not be affected by
my subsequent disability or incompetence. I may revoke this Power of
Attorney by written notice delivered, in person or by nationally
recognized courier, to the attention of the SVP, General Counsel of
Sage Therapeutics, Inc.
/s/ Kimi Iguchi
___________________________________________________
(Signature of Executive Officer or Director)
Name: Kimi Iguchi, Chief Financial Officer
Date: 1/23/2019